While targeted therapies have vastly improved the survival of ER/PR-(Estrogen/Progesterone receptor) and HER2/ErbB2-positive breast cancers, TNBC, which is defined by the absence of these hormone receptors and of HER2 amplification [7], remains a major clinical challenge with no efficient targeted therapy [8]. Here, ERBB2 is linked to breast cancer.